News @ Qprotyn
This patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
Upgrade your mAb from IV to SubQ.
Re-imagine your biologic API delivered subcutaneously in a single dose up to 375mg in a 1.5mL syringe.
Thank you! We will get back to you shortly.